Affimed N.V. (NASDAQ:AFMD) Sellers Decreased Their Shorts By 17.93% As Of Apr 17, 2018

April 17, 2018 - By Darrel Chase

Affimed N.V. (NASDAQ:AFMD) recorded a decrease of 17.93% in shares shorted. It was published in April by FINRA the 397,800 shares shorted on AFMD. The 484,700 previous shares are down with 17.93%. With Average volume 393,700, AFMD’s former position will take 1 days to restore. Affimed N.V.’s shares shorted float is 1.57%.

$2.1 was the last price.It’s downtrending since April 17, 2017 and is 25.96% down. AFMD underperformed the S&P 500 by 37.51%.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally.The firm is valued at $131.02 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.Last it reported negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.